B103. ILD: THERAPY

Rates of Adherence and Persistence of Antifibrotic Therapies in the U.S. Medicare Population

Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4094 M. Corral, S. Reddy, E. Chang, M. Broder, S. Gokhale, K. Raimundo

Outcome of Third Line Therapies in Sarcoidosis

Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4083 R. Baughman, Madison Sturdivant, Lisa Grate, E. Lower

Baseline Characteristics of All Patients Randomized in a Phase IIb Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension

Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4092 J. Behr, S. Nathan, S. Harari, W. Wuyts, N. M. Bishop, Demosthenes Bouros, K. Antoniou, J. Guiot, M. Kramer, K. Kirchgaessler, M. Bengus, F. Gilberg, A. Wells